FDA Authorization for the Next Generation Sequencer Essay

FDA Authorization for the Next Generation Sequencer - move ExampleIt is apparent that different people respond differently to different drugs, and the character of genome sequencing will non only reveal the nature and susceptibility of illnesses, but it will also provide physicians with the specific prescriptions require (Collins & Hamburg, 2013). This technology could be used to develop the most appropriate treatment combinations for different patients suffering from cancer. With genomic sequencing, it is possible for doctors to identify the nature of cancer and predict its spreading patterns hence, the new system will be submissive in helping doctors deal with different forms of cancer more appropriately (Collins & Hamburg, 2013). The authorization of marketing for the genomic sequencer is a step closer to developing clinical care that is individually oriented. It is however, clear that some issues the likes of the absence of legal and regulatory policies for the new system will arise (Collins & Hamburg, 2013). There are signs that the administration are committed to developing the most conducive policies to enable the effective and ethical application of the genomic sequencer. The use of the genomics sequencing technology has the potential to attract ethical issues like insurance companies being acquainted with genomic information active their clients, which could cause the development of exempted services that might be discriminating (Collins & Hamburg, 2013). Access to genomic information by physicians whitethorn also lead to substandard applications of the system. It is required that the development of accurate genomic information must be reach through thorough processes that may require recurrent experimentation (Collins & Hamburg, 2013). The FDA is collaborating with the National Institute for Standards and Technology to founding the required interpretive material for physicians.